

Helix BioMedix Appoints Dermatology Scientific Advisory Board

Distinguished Group of Dermatologists to Advise on Advancing the Company's Pipeline

Feb 20, 2007 - Bothell, Washington

Helix BioMedix Inc. (OTC Bulletin Board: HXBM), a developer of bioactive peptides, today announced the creation of a Dermatology Scientific Advisory Board to provide advice on scientific, clinical, and regulatory matters regarding the company's patented peptide technology as it applies to the cosmetic care and therapeutic treatment of the skin.

Joining Lori Bush, Chief Operating Officer and Dr. Timothy Falla, Chief Scientific Officer of Helix BioMedix are three distinguished and accomplished dermatologists who maintain clinical practices while contributing to the body of scientific research that is advancing the treatment of skin. Helix BioMedix's independent advisors include Dr. Zoe Diana Draelos, Dr. Barbara Gilchrest and Dr. Mark Lebwohl.

"We are very pleased to have assembled this team of knowledgeable and highly respected professionals to share their expertise and offer guidance as part of our Scientific Advisory Board," said R. Stephen Beatty, President and Chief Executive Officer. "During the past year, Helix BioMedix has made numerous advancements in the development of our cosmeceutical and pharmaceutical peptide technologies, particularly in the areas of anti-aging skin care, acne treatment and management of a variety of dermatoses. The extensive scientific and medical expertise of this Board should prove invaluable as we move technology from laboratory to clinical development. We are privileged to have each of these individuals associated with Helix BioMedix."

Dermatology Scientific Advisory Board Members:

Lori Bush, Chief Operating Officer of Helix Biomedix. Ms. Bush is a 25 year veteran of the medical and consumer health and beauty industries. Prior to joining Helix in October 2006 she was President of Nu Skin, the multi-national personal care products division of Nu Skin Enterprises. As a member of their executive committee, Ms. Bush was instrumental in developing Nu Skin Enterprises' growth strategy while strengthening core competencies in the areas of marketing and product development. Ms. Bush also held several leadership positions within the skin care franchises of the Johnson & Johnson Consumer Products Companies. In her role as Helix BioMedix's COO, Ms. Bush employs her expertise in the commercialization of the company's skin care peptides.

Dr. Zoe Diana Draelos, Clinical Associate Professor of Dermatology, Wake Forest University School of Medicine. Dr. Draelos is the author of the textbook *Cosmetics in Dermatology*, now in its second edition, and has contributed chapters on cosmetics in 23 textbooks, writing 260 published papers, and currently serving on five journal editorial boards. She is the editor of *The Journal of Cosmetic Dermatology* and founded Dermatology Consulting Services to provide education, perform adverse reaction evaluation, and conduct clinical studies in association with the industry.

Dr. Barbara Gilchrest, Professor and Chair, Department of Dermatology at Boston University School of Medicine and Chief of Dermatology at the Boston Medical Center (BMC). A Harvard Medical School graduate, Dr. Gilchrest is board certified in Internal Medicine and Dermatology. She is the author or editor of

11 books on skin aging, photoaging, and UV effects on skin and author of over 400 original articles, reviews, editorials, and invited textbook chapters. She is a section editor for the *Journal of Investigative Dermatology*, the leading research journal in the field, and serves on the editorial board of 5 other dermatology or aging journals. Her current research interests range from the molecular basis of skin aging to DNA damage responses in skin to clinical studies of photodynamic therapy for the prevention and treatment of photocarcinogenesis. Dr. Gilcrest is a member of the Institute of Medicine of the National Academies of Science.

Timothy Falla, Ph.D., Vice President and Chief Scientific Officer of Helix BioMedix. Dr. Falla joined the Company as Chief Scientific Officer in June 2001 and is responsible for developing the Company's science and technology and for its application to clinical and non-clinical product candidates. Prior to joining the Company, Dr. Falla was employed by IntraBiotics Pharmaceuticals, Inc., a biopharmaceutical company, where, as principal scientist he led a multi-disciplinary research team focused on antibacterial drug discovery and development. Prior to his tenure with IntraBiotics, Dr. Falla held research associate positions at the University of British Columbia and The Antimicrobial Research Centre at the University of Leeds. Dr. Falla's work in the areas of infectious disease and peptide development has been described in over 70 published papers, book chapters and reviews.

Dr. Mark Lebwohl, Professor and Chairman, Department of Dermatology at Mount Sinai School of Medicine. Dr. Lebwohl is past president of the New York State Society of Dermatology and immediate past-chairman of the Psoriasis Task Force of the American Academy of Dermatology. He is also a member of the medical advisory board of the National Psoriasis Foundation and editor of *Psoriasis Forum* and *Psoriasis Advance*, the patient bulletin of the National Psoriasis Foundation. He is the "Medical Pearl" feature editor and as well as assistant editor of *The Journal of the American Academy of Dermatology*. Dr. Lebwohl has written several books on dermatology, authored or co-authored over 400 publications and is actively involved in clinical trials of new dermatologic treatments.

About Helix BioMedix

Helix BioMedix, Inc. is a biopharmaceutical company that has a portfolio of issued patents that covers six distinct classes of peptides, covering over 100,000 unique peptide sequences. The company's mission is to become the industry leader in developing and commercializing small proteins known as bioactive peptides. The antimicrobial and wound healing properties of these peptides qualify them for inclusion in a wide range of both pharmaceutical and consumer products. The company is currently focused on the development of selected peptides as topical anti-infectives and in wound healing. Non-pharmaceutical applications being pursued by Helix BioMedix include adjuvants for cosmetics/cosmeceuticals, personal care, plant health, animal health and wide-spectrum biocides. More information about the company and its proprietary peptides can be found on the company's website at www.helixbiomedix.com.

Important Notice

This press release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding activities, events or developments that the company expects, believes or anticipates may occur in the future, including statements related to our potential growth, product development and commercialization and revenue. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the company's ability to successfully raise additional capital,

enter into revenue generating license agreements, continue its research and development efforts, including pre-clinical and clinical studies, and general economic conditions. Additional assumptions, risks and uncertainties are described in detail in our reports and other filings with the Securities and Exchange Commission. Such filings are available on our website or at www.sec.gov. Readers are cautioned that such forward-looking statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances.

Contact:

Investor Relations:

Cameron Associates

Alison Ziegler 212-554-5469

alison@cameronassoc.com